前列腺癌骨寡转移患者行减瘤性根治性前列腺切除术的肿瘤学结局
回顾性队列纳入2005至2016年本中心111例寡转移前列腺癌患者,35例行减瘤性根治性前列腺切除术联合雄激素剥夺治疗,76例单用雄激素剥夺治疗,中位随访35个月,两组前列腺特异性抗原复发无生存、临床进展无生存及癌症特异性生存差异均未达统计学显著。
要点
- 寡转移定义为99mTc骨扫描发现5个或以下转移灶且治疗前影像无可疑内脏受累。
- 两组前列腺特异性抗原下降速度、半衰期及最低值差异均无统计学意义。
- 减瘤性根治性前列腺切除术未显示显著肿瘤学获益,需审慎选择手术候选者。
核心结论
- 本研究中,寡转移前列腺癌患者未从减瘤性根治性前列腺切除术中检测到显著获益。
- 面对当前趋势,需审慎考虑减瘤性手术的候选者选择,并应通过纳入更多预后因素进一步细化选择标准。
研究设计与样本
- 回顾性队列研究,纳入2005至2016年本中心连续诊断的111例寡转移前列腺癌患者。
- 35例接受减瘤性根治性前列腺切除术联合雄激素剥夺治疗,76例单用雄激素剥夺治疗。
- 寡转移定义为99mTc骨扫描发现5个或以下转移灶且治疗前影像无可疑内脏受累。
- 采用Kaplan-Meier法分析肿瘤学结局。
主要发现
- 两组中位随访均为35个月。
- 全队列分析中,两组前列腺特异性抗原下降速度(P = .167)、半衰期(P = .263)及最低值(P = .196)差异均无统计学意义。
- 两组前列腺特异性抗原复发无生存(P = .184)、临床进展无生存(P = .118)及癌症特异性生存(P = .773)差异均未达统计学显著。
- 预设亚组分析结果相似:较低前列腺特异性抗原组(0-100 ng/mL,P = .543)、较低Gleason评分组(6-7,P = .266)、较低临床T分期组(2-3期,P = .962)、较低影像学N分期组(0期,P = .364)。
临床怎么用
- 作者认为,面对当前趋势,需审慎考虑减瘤性手术的候选者选择,并应通过纳入更多预后因素进一步细化选择标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the role of cytoreductive radical prostatectomy (CRP) for locally resectable and distant oligometastatic prostate cancer (CaP). PATIENTS AND METHODS: Oligometastases were defined as the presence of 5 or fewer metastatic lesions detected on 99mTc bone scan and no suspicious visceral involvement at pretreatment imaging. Clinical data on 111 consecutive patients who were diagnosed as oligometastatic CaP in our center from 2005 to 2016 was retrospectively collected. In this retrospective cohort study, 35 patients underwent CRP and androgen deprivation therapy, and 76 patients underwent androgen deprivation therapy alone. Oncological outcomes were analyzed by employing Kaplan-Meier method. RESULTS: The median follow-up of both groups was 35 months. In whole cohort analyses, prostate-specific antigen (PSA) decrease velocity (P = .167), PSA half-time (P = .263), and PSA nadir (P = .196) were not significantly different between 2 groups. Meanwhile, the differences in oncological outcomes between 2 groups did not reach statistical significance with regard to PSA relapse-free survival (P = .184), clinical progression-free survival (P = .118), and cancer-specific survival (P = .773). In addition, similar results were also observed in prespecified subgroup analyses (lower PSA group [0-100 ng/mL, P = .543], lower Gleason score group [6-7, P = .266], lower clinical T stage group [2-3 stage, P = .962], lower radiological N stage group [0 stage, P = .364]). CONCLUSION: In our study, significant benefit from CRP has not been detected in patients with oligometastatic CaP. Facing current trend, it demands deliberate consideration to select candidates for cytoreductive surgery, and the selection criteria should be further refined by incorporating additional prognostic factors.
引用
- Lan T, Chen Y, Su Q, et al. Oncological Outcome of Cytoreductive Radical Prostatectomy in Prostate Cancer Patients With Bone Oligometastases. Urology. 2019. PMID: 31181273. doi:10.1016/j.urology.2019.03.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。